ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Add and Read Reviews
Compounding Pharmacy Product Reviews
Compounding Pharmacy FDA inspections
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="maxadvance" data-source="post: 51474" data-attributes="member: 12434"><p>Looks like noones perfect, geez, </p><p></p><p><a href="http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOperationsandPolicy/ORA/ORAElectronicReadingRoom/UCM478202.pdf" target="_blank">http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOperationsandPolicy/ORA/ORAElectronicReadingRoom/UCM478202.pdf</a></p><p></p><p>DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:</p><p></p><p>OBSERVATION 1 "'·:".</p><p>There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.</p><p></p><p>Specifically, the sterility test dated 9/10/15 which was conducted by your contract laboratory determined that Lipo-C Injectable, lot # 17478 (Production date: 8112/15, Beyond Use Date: 1/31/16) was not sterile. Subsequent speciation via dated 9/22/15 which was also performed by the contract laboratory determined that the contaminating organism was Streptomyces galbus. An investigation performed by the contracting laboratory dated 9/3/15 documented that the source of the contamination was caused by "external error". A second sample tested for sterility from the same lot passed sterility testing.</p><p></p><p>There was no documentation of an investigation by your firm into the initial failing sterility result or potential impact on lots of injectable drug products produced on the same date. For example, the following lots of injectable drug products were also produced on 8/12/15:</p><p></p><p>•••Glutathione, 200mg/ml, lot#17477</p><p>GHRP-2/GHRP-6/Sermorelin,lot # 17475</p><p>GHRP-2/GHRP-6/Sermorelin,lot #17473</p><p></p><p>OBSERVATION 2</p><p></p><p>Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.</p><p></p><p>A) Media Fills </p><p></p><p>SOP #T08.06 entitled, ''Sterile Compounding Process Validation " (Undated) documents, in part, that a total of[EJI*- will be used to conduct media fills.</p><p></p><p>1) Review of media fills conducted between 8/4/14 and 10/2/15 revealed that the media fills were not representative of actual production processes in that:</p><p></p><p>a. The media fills failed to simulate a lot with the maximum number of vials (i.e. (b) (4 )vials)b. </p><p></p><p>The number and type of interventions was not included (i.e. breaks in processing to clean up spillage)c. The aseptic assembly of equipment (e.g., at start-up, during processing) was not included.</p><p></p><p>d. The preparation/formulation of the API was not simulated.</p><p>2) Media fills for lyophilized products were not conducted (i.e. Human Chorionic Gonadotropin and Sermorelin)</p><p></p><p>B)Sterilizationto sterilize rubber stoppers, caps, andalcohol" tun.u;:n..uJ documents thathas not been performed to rt"'.'""'a""'t"'(b ) (4)</p><p>D ) LyophilizerYour firm utilizes a for the lyophilization of injectable drug products.Your firm failed to drug products such as Human ChorionicGonadotropin Lyophilized and Sermorelin used.</p></blockquote><p></p>
[QUOTE="maxadvance, post: 51474, member: 12434"] Looks like noones perfect, geez, [URL]http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOperationsandPolicy/ORA/ORAElectronicReadingRoom/UCM478202.pdf[/URL] DURING AN INSPECTION OF YOUR FIRM WE OBSERVED: OBSERVATION 1 "'·:". There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed. Specifically, the sterility test dated 9/10/15 which was conducted by your contract laboratory determined that Lipo-C Injectable, lot # 17478 (Production date: 8112/15, Beyond Use Date: 1/31/16) was not sterile. Subsequent speciation via dated 9/22/15 which was also performed by the contract laboratory determined that the contaminating organism was Streptomyces galbus. An investigation performed by the contracting laboratory dated 9/3/15 documented that the source of the contamination was caused by "external error". A second sample tested for sterility from the same lot passed sterility testing. There was no documentation of an investigation by your firm into the initial failing sterility result or potential impact on lots of injectable drug products produced on the same date. For example, the following lots of injectable drug products were also produced on 8/12/15: •••Glutathione, 200mg/ml, lot#17477 GHRP-2/GHRP-6/Sermorelin,lot # 17475 GHRP-2/GHRP-6/Sermorelin,lot #17473 OBSERVATION 2 Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process. A) Media Fills SOP #T08.06 entitled, ''Sterile Compounding Process Validation " (Undated) documents, in part, that a total of[EJI*- will be used to conduct media fills. 1) Review of media fills conducted between 8/4/14 and 10/2/15 revealed that the media fills were not representative of actual production processes in that: a. The media fills failed to simulate a lot with the maximum number of vials (i.e. (b) (4 )vials)b. The number and type of interventions was not included (i.e. breaks in processing to clean up spillage)c. The aseptic assembly of equipment (e.g., at start-up, during processing) was not included. d. The preparation/formulation of the API was not simulated. 2) Media fills for lyophilized products were not conducted (i.e. Human Chorionic Gonadotropin and Sermorelin) B)Sterilizationto sterilize rubber stoppers, caps, andalcohol" tun.u;:n..uJ documents thathas not been performed to rt"'.'""'a""'t"'(b ) (4) D ) LyophilizerYour firm utilizes a for the lyophilization of injectable drug products.Your firm failed to drug products such as Human ChorionicGonadotropin Lyophilized and Sermorelin used. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Add and Read Reviews
Compounding Pharmacy Product Reviews
Compounding Pharmacy FDA inspections
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top